| Binary variables |
| Male |
19 |
43.6 |
0.023 |
0.91 (0.78, 1.06) |
0.206 |
0.319 |
| Female |
19 |
43.6 |
0.023 |
1.10 (0.95, 1.28) |
0.206 |
0.319 |
| Smoking history |
4 |
55.7 |
0.079 |
0.71 (0.37, 1.38) |
0.314 |
0.166 |
| Previous chest surgery |
3 |
45.7 |
0.159 |
1.07 (0.76, 1.51) |
0.686 |
0.680 |
| Donor Men |
2 |
0 |
0.372 |
0.59 (0.37, 0.92) |
0.022 |
<0.001 |
| Pulmonary fibrosis |
14 |
30.2 |
0.135 |
1.34 (1.09, 1.65) |
0.006 |
0.912 |
| Chronic obstructive pulmonary disease |
12 |
51.7 |
0.019 |
0.78 (0.54, 1.11) |
0.164 |
0.015 |
| Interstitial lung disease |
6 |
47.5 |
0.090 |
1.03 (0.74, 1.42) |
0.875 |
0.703 |
| Pulmonary hypertension |
6 |
0 |
0.552 |
1.19 (0.74, 1.89) |
0.473 |
0.239 |
| Alpha-1-anti-trrysine deficiency |
3 |
27.3 |
0.253 |
0.69 (0.33, 1.45) |
0.328 |
0.623 |
| Bronchiectasis |
6 |
43.2 |
0.117 |
1.04 (0.59, 1.82) |
0.902 |
0.679 |
| Bronchiolitis obliterans |
2 |
0 |
0.320 |
1.22 (0.41, 3.59) |
0.722 |
<0.001 |
| Hypertension |
15 |
0 |
0.467 |
1.30 (1.07, 1.58) |
0.007 |
0.514 |
| Diabetes mellitus |
18 |
0 |
0.633 |
1.18 (0.97, 1.45) |
0.104 |
0.284 |
| Dyslipidemia |
5 |
0 |
0.887 |
1.58 (0.95, 2.63) |
0.077 |
0.200 |
| Chronic kidney failure |
5 |
47.7 |
0.105 |
1.05 (0.62, 1.77) |
0.862 |
0.303 |
| Pulmonary hypertension |
4 |
0 |
0.606 |
1.33 (0.90, 1.96) |
0.149 |
0.017 |
| Peripheral vascular disease |
2 |
0 |
0.732 |
1.06 (0.24, 4.61) |
0.038 |
<0.001 |
| Cerebrovascular disease |
2 |
46.6 |
0.171 |
0.48 (0.08, 2.85) |
0.032 |
<0.001 |
| Coronary artery disease |
5 |
0 |
0.416 |
1.23 (0.85, 1.77) |
0.269 |
0.163 |
| Creatinine clearance > 90 mL min |
2 |
38.3 |
0.203 |
1.49 (0.99, 2.24) |
0.055 |
<0.001 |
| Recipient CMV+ |
2 |
13 |
0.284 |
0.94 (0.67, 1.32) |
0.724 |
<0.001 |
| Pre-op MV |
6 |
0 |
0.655 |
3.30 (1.84, 5.90) |
<0.001 |
0.061 |
| Pre-op ECMO |
11 |
0 |
0.634 |
3.70 (2.51, 5.45) |
<0.001 |
0.510 |
| Double lung transplantation |
15 |
53.3 |
0.008 |
1.91 (1.45, 2.53) |
<0.001 |
0.949 |
| Single lung transplantation |
9 |
44.1 |
0.074 |
0.52 (0.42, 0.64) |
<0.001 |
0.137 |
| Intra-op ECMO support |
13 |
39.8 |
0.068 |
1.19 (0.97, 1.46) |
0.099 |
0.808 |
| Cardiopulmonary bypass support |
5 |
0 |
0.991 |
1.82 (1.38, 2.40) |
<0.001 |
0.455 |
| Cardiovascular events |
4 |
3.4 |
0.376 |
1.50 (1.15, 1.96) |
0.003 |
0.308 |
| Blood cell transfusion |
2 |
7.7 |
0.298 |
1.93 (1.00, 3.75) |
0.051 |
<0.001 |
| Intra-op hypotension |
3 |
30.7 |
0.236 |
2.70 (1.42, 5.14) |
0.003 |
0.823 |
| Aprotinin use |
3 |
52.3 |
0.123 |
1.67 (0.82, 3.38) |
0.157 |
0.040 |
| Post-op ECMO |
7 |
0 |
0.773 |
1.90 (1.20, 3.01) |
0.006 |
0.681 |
| Reoperation |
2 |
0 |
0.550 |
1.89 (0.91, 3.94) |
0.089 |
<0.001 |
| Sepsis |
6 |
0 |
0.674 |
3.20 (2.16, 4.73) |
<0.001 |
0.012 |
| Stage 3 primary graft dysfunction |
3 |
76.8 |
0.013 |
2.29 (0.86, 6.10) |
0.096 |
0.035 |
| Primary graft dysfunction |
2 |
44.4 |
0.180 |
5.59 (2.62, 11.93) |
<0.001 |
<0.001 |
| Multiple organ dysfunction during ICU |
2 |
0 |
0.422 |
11.11 (4.17, 29.61) |
<0.001 |
<0.001 |
| pH < 7.20 on ICU admission |
2 |
46.8 |
0.170 |
0.87 (0.39, 1.90) |
0.720 |
<0.001 |
| Lactate > 3 mmol L |
2 |
18.3 |
0.269 |
2.52 (1.50, 4.25) |
<0.001 |
<0.001 |
| Mechanical ventilation > 3 d |
2 |
0 |
0.344 |
2.68 (1.53, 4.69) |
0.001 |
<0.001 |
| Dialysis |
5 |
0 |
0.551 |
12.79 (6.11, 26.8) |
<0.001 |
0.415 |
| Repeat chest surgery |
2 |
32.6 |
0.223 |
0.92 (0.40, 2.11) |
0.846 |
<0.001 |
| Pneumonia |
2 |
0 |
0.734 |
4.04 (1.90, 8.61) |
<0.001 |
<0.001 |
| Ganciclovir |
2 |
0 |
0.659 |
1.16 (0.61, 2.21) |
0.654 |
<0.001 |
| Basiliximab |
2 |
0 |
0.816 |
1.02 (0.61, 1.70) |
0.945 |
<0.001 |
| Cyclosporine |
4 |
73.2 |
0.011 |
0.73 (0.40, 1.32) |
0.296 |
0.668 |
| Supra-therapeutic whole-blood tacrolimus trough concentration |
2 |
0 |
0.738 |
2.27 (1.16, 4.48) |
0.017 |
<0.001 |
| Tacrolimus |
4 |
25.5 |
0.258 |
1.09 (0.81, 1.45) |
0.572 |
0.680 |
| Amphotericin B intravenous infused |
2 |
39.5 |
0.199 |
2.88 (1.5, 5.54) |
0.001 |
<0.001 |
| Continuous variables |
| Age, year |
19 |
20.3 |
0.207 |
−0.04 (−0.11, 0.04) |
0.319 |
0.861 |
| BMI, kg/m2
|
14 |
24.1 |
0.194 |
−0.03 (−0.13, 0.07) |
0.535 |
0.196 |
| Donor Age, year |
3 |
0 |
0.949 |
0.03 (−0.14, 0.21) |
0.719 |
0.669 |
| FEV1, % |
2 |
0 |
0.554 |
−0.35 (−0.83, 0.12) |
0.144 |
<0.001 |
| Lung allocation score |
4 |
0 |
0.394 |
0.34 (0.24, 0.45) |
<0.001 |
0.866 |
| Pre-op APACHE II score |
4 |
76.7 |
0.005 |
0.19 (−0.26, 0.64) |
0.407 |
0.482 |
| SCr, mg/dl |
13 |
86.9 |
<0.001 |
−0.05 (−0.32, 0.22) |
0.715 |
0.325 |
| GFR, mL/min |
12 |
82.2 |
<0.001 |
0.21 (−0.02, 0.45) |
0.068 |
0.013 |
| ALT, IU/L |
2 |
43.8 |
0.182 |
−0.05 (−0.37, 0.27) |
0.755 |
<0.001 |
| AST, IU/L |
2 |
0 |
0.666 |
0.13 (−0.19, 0.45) |
0.430 |
<0.001 |
| WBC, ×109/L |
2 |
0 |
0.884 |
0.2 (−0.04, 0.43) |
0.108 |
<0.001 |
| Platelets, ×109/L |
2 |
0 |
0.439 |
−0.04 (−0.28, 0.2) |
0.740 |
<0.001 |
| Hemoglobin, g/L |
5 |
61.6 |
0.034 |
−0.29 (−0.58, 0.00) |
0.051 |
0.452 |
| Total bilirubin, mg/dL |
2 |
55.7 |
0.133 |
0.07 (−0.34, 0.47) |
0.742 |
<0.001 |
| BUN, mg/dL |
2 |
0 |
0.349 |
0.03 (−0.21, 0.27) |
0.818 |
<0.001 |
| Operating time, min |
13 |
67.1 |
<0.001 |
0.22 (0.03, 0.4) |
0.023 |
0.365 |
| Waitlist time, d |
2 |
10.1 |
0.292 |
−0.02 (−0.16, 0.12) |
0.767 |
<0.001 |
| Mean arterial pressure, mmHg |
2 |
0 |
0.758 |
−0.02 (−0.30, 0.27) |
0.901 |
<0.001 |
| Blood transfusions, ml |
5 |
34.8 |
0.189 |
0.12 (−0.08, 0.32) |
0.249 |
0.801 |
| Transfusion RBC, ml |
5 |
52.6 |
0.077 |
0.33 (0.08, 0.58) |
0.011 |
0.676 |
| Transfusion Plasma, ml |
4 |
49 |
0.141 |
0.38 (0.12, 0.64) |
0.004 |
0.065 |
| Transfused platelets, ml |
3 |
0 |
0.784 |
−0.15 (−0.45, 0.16) |
0.346 |
<0.001 |
| Total crystalloid, mL |
2 |
0 |
0.527 |
−0.02 (−0.28, 0.25) |
0.903 |
<0.001 |
| Loss of blood, mL |
6 |
56.4 |
0.043 |
0.16 (−0.12, 0.45) |
0.264 |
0.916 |
| Cardiopulmonary bypass, min |
2 |
29.7 |
0.233 |
0.07 (−0.09, 0.24) |
0.390 |
<0.001 |
| Ischemia time, min |
6 |
53 |
0.059 |
0.20 (0.00, 0.40) |
0.050 |
0.475 |
| Median TAC concentration, ng/mL |
2 |
0 |
0.937 |
0.60 (0.34, 0.85) |
<0.001 |
<0.001 |
| Intraoperative fluid intake, ml |
2 |
89.3 |
0.002 |
−0.12 (−1.54, 1.30) |
0.868 |
<0.001 |
| Intra-op Fluid balance, ml |
3 |
63.9 |
0.063 |
0.39 (−0.10, 0.87) |
0.117 |
0.059 |
| Duration of ECMO support, d |
4 |
0 |
0.758 |
0.36 (0.16, 0.57) |
<0.001 |
0.132 |
| Duration of MV, d |
12 |
77.9 |
<0.001 |
0.47 (0.20, 0.74) |
0.001 |
0.624 |
| Day 1 SCr levels, mg/dL |
2 |
25.6 |
0.246 |
0.77 (0.17, 1.37) |
0.012 |
<0.001 |
| Day 3 SCr levels, mg/dL |
2 |
79.6 |
0.027 |
0.53 (−0.67, 1.73) |
0.384 |
<0.001 |
